Cumberland Pharmaceuticals Falls 46% on Ifetroban Filing Plans

Why Cumberland Pharmaceuticals Stock Fell Today

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) fell 46% after hours to $4.56 after announcing plans to seek approval for Ifetroban. Trading totaled about 480,000 shares, as holders weighed the unresolved path to approval. The candidate targets cardiomyopathy, a heart-muscle disease, linked to Duchenne muscular dystrophy, a genetic disease that can cause muscle weakness and heart problems.

What Cumberland Pharmaceuticals Inc. Does

Cumberland develops drug candidates for rare diseases and other serious medical needs. Ifetroban remains a candidate for Duchenne-related cardiomyopathy, not an approved treatment.

Cumberland Ifetroban Approval Plan

A New Drug Application asks the Food and Drug Administration (FDA), the US drug regulator, to approve a medicine. Cumberland proposes using its Ifetroban trial plus two natural-history databases, which track disease progression without the treatment. The FDA allowed early submission of completed sections, called rolling review, but questioned the evidence and requested more analysis of missing data.

Cumberland Ifetroban Trial Findings

The 12-month FIGHT DMD trial, Cumberland’s Ifetroban study, measured how much blood the heart’s main pumping chamber sends out each beat. The high-dose group showed a 5.4% absolute improvement versus patients given a placebo, a dummy treatment, and matched untreated patients. Here, absolute means the difference between the groups’ heart-pumping measurements, not a percent increase calculated from the comparison group’s result.

Quick Financial Overview

Cumberland reports revenue but remains unprofitable. It is a micro-cap, meaning a very small publicly traded company, with a market value of $68.3M, the combined value of its shares. Its latest report showed $3.9M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.

Cumberland Pharmaceuticals Revenue And Earnings

For the same quarter, Cumberland reported $166,458.00 in revenue and a net loss of $4.3M.

Cumberland Pharmaceuticals Stock Chart After Record Drop

CPIX has fallen from the mid $7s over the past month, though it remains up 34% over six months and up 60% over the year. Today, the stock reached a high in the high $7s this morning before touching around $4.25. That made today the biggest daily move in the last year.

Conclusion

Cumberland has not given a date for its planned rolling submission. Sending the application would begin formal FDA review, while a later decision would show whether the agency considers the evidence strong enough to approve Ifetroban for this heart condition.